Celgene Dips Into The Antibody Well Once More, Partners With Sutro
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
You may also be interested in...
Deal Watch: AbbVie Cancels Shire Buyout, Blaming U.S. Tax Policy Revisions
Actavis potentially bolsters its GI franchise by optioning rights to peptide ghrelin agonist relamorelin and also the opportunity to buy out Rhythm Health. Meanwhile, Celgene increases its stake in Sutro and Janssen joins the Ebola fight.
Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates
Celgene reports its apremilast is attracting more new psoriatic arthritis patients than branded leaders in the space. Sales for its first full quarter amounted to $18 million and new indication in psoriasis should start to contribute later this year, company says.
With $26M Series D, Antibody Platform Developer Sutro Biopharma To Prep Its Own Products
The decade-old San Francisco antibody developer previously has relied on platform partnerships, but now will attempt to bring a candidate – likely a bi-specific antibody – into the clinic within 18 months. Six investors, including three corporate VCs, composed the returning syndicate.